> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# GT Medical Expanded Use for GammaTile Therapy
- URL: https://www.fdaweb.com/gt-medical-expanded-use-for-gammatile-therapy/
- Published: 2020-01-27T12:00:00.000Z
- Updated: 2026-09-14T16:00:03.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5145934

FDA has cleared a GT Medical Technologies 510(k) for an expanded indication for GammaTile Therapy — surgically targeted radiation therapy in patients with newly diagnosed malignant brain tumors. GammaTile features a bioresorbable, conformable, 3D-collagen tile and uniform radiation source, Cesium-131, GT Medical says. It is placed at the end of excision surgery to immediately target residual tumor cells while limiting the impact of radiation on healthy brain tissue. The device also limits side effects typically associated with radiation therapy, including hair loss, it says. GammaTile gained 510(k) clearance 7/2018 for treating all types of recurrent brain tumors.